Abstract
Background: Expression of TRAP1, a member of the HSP90 chaperone family, has been implicated in tumour protective effects, based on its differential mitochondrial localization and function. Design: This work was designed to provide new insights into the pathways involved in TRAP1-provided cytoprotection on NSCLC. For this, TRAP1-depleted A549 human NSCLC cells and MRC-5 normal lung fibroblasts were produced using a siRNA approach and main cellular quality control mechanisms were investigated. Results: TRAP1-depleted A549 cells displayed decreased cell viability likely due to impaired mitochondrial function including decreased ATP/AMP ratio, oxygen consumption and membrane potential, as well as increased apoptotic indicators. Furthermore, the negative impact of TRAP1 depletion on mitochondrial function was not observed in normal MRC-5 lung cells, which might be due to the differential intracellular localization of the chaperone in tumour versus normal cells. Additionally, A549 TRAP1-depleted cells showed increased autophagic flux. Functionally, autophagy inhibition resulted in decreased cell viability in both TRAP1-expressing and TRAP1-depleted tumour cells with minor effects on MRC-5 cells. Conversely, autophagy stimulation decreased cell viability of both A549 and MRC-5 TRAP1-expressing cells while in A549 TRAP1-depleted cells, increased autophagy augmented viability. Conclusions: Our results show that even though TRAP1 depletion affects both normal MRC-5 and tumour A549 cell proliferation, inhibition of autophagy per se led to a decrease in tumour cell mass, while having a reduced effect on the normal cell line. The strategy of targeting TRAP1 in NSCLC shows future potential therapeutic applications.
Original language | English (US) |
---|---|
Article number | e12900 |
Journal | European Journal of Clinical Investigation |
Volume | 48 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2018 |
Bibliographical note
Funding Information:Sponsored by the European Regional Development Fund (ERDF) through the COMPETE 2020—Operational Programme for Competitiveness and Internationalisation, and Portuguese national funds via FCT—Funda©cão para a Ciên-cia e a Tecnologia, projects POCI-01-0145-FEDER-016390:CANCEL STEM, and IF/01316/2014. Also supported by POCI-01-0145-FEDER-007440 and PCTI project (Government of the Principality of Asturias and ERDF) with reference GRUPIN14-071. The funding agencies had no role in study design, experimentation or writing the manuscript. The authors have no conflict of interests.
Funding Information:
European Regional Development Fund (ERDF) through the COMPETE 2020— Operational Programme for Competitiveness and Internationalisation, and Portuguese national funds via FCT— Funda©cão para a Ciência e a Tecnologia, Grant/Award Number: POCI-01-0145-FEDER-016390 (CANCELSTEM), IF/ 01316/2014, POCI-01-0145-FEDER-007440; PCTI project (Government of the Principality of Asturias and ERDF), Grant/ Award Number: GRUPIN14-071
Publisher Copyright:
© 2018 Stichting European Society for Clinical Investigation Journal Foundation
Keywords
- TRAP1
- apoptosis
- autophagy
- cathepsin B
- lung cancer
- macroautophagy